Jeena Sikho Lifecare Limited (JSLL) stands as a prominent and leading provider of Ayurvedic healthcare systems in India. With a decade of experience, the company is dedicated to building a healthier India by integrating traditional Ayurvedic treatments with modern healthcare services. Headquartered in Zirakpur, Punjab, JSLL has established itself as a reputable name in the Ayurvedic healthcare sector.
Originally incorporated as "Jeena Sikho Lifecare Private Limited" on May 29, 2017, it transitioned to a public limited company as "Jeena Sikho Lifecare Limited" on July 05, 2021. Founded by Acharya Manish Ji, the company's core mission is to promote health and well-being across the nation through its comprehensive approach.
JSLL operates an extensive network of healthcare facilities, comprising 36 hospitals and 74 clinics/daycare centers spread across 21 states and over 100 cities in India. The company's hospitals currently have 1,530 operational beds, with an additional 518 beds in the pipeline for future expansion.
Beyond clinical services, Jeena Sikho Lifecare Limited is deeply involved in the development and distribution of over 250 herbal and Ayurvedic products. The company actively conducts health check-up camps and yoga sessions to raise public awareness about health issues and promote preventative care.
The company's product line is marketed under established brands, notably Shuddhi and Origine Naturspired. Shuddhi focuses on Ayurvedic herbs and products designed to address a wide spectrum of ailments, emphasizing detoxification and natural remedies. Origine Naturspired offers a range of beauty and wellness products that promote nourishment for skin, hair, and overall health through natural ingredients.
Key products include the Shuddhi Kit, Shuddhi 32 Herbs Tea, Shuddhi Addiction Free Kit, Shuddhi BP Package, Shuddhi Diabetes Care Package, and Shuddhi Divya Sanjeevani Anti-Viral. The Shuddhi Kit, in particular, is an all-encompassing Ayurvedic package designed to aid digestion, boost immunity, balance hormones, and facilitate bodily detoxification.
Jeena Sikho Lifecare Ltd has demonstrated robust financial performance, characterized by significant growth metrics and strong profitability.
* Market Capitalization: ₹5,300.18 Crore (as of July 2025). The company's market capitalization has seen substantial growth, reported at ₹6,577 Crore with a 136% increase in the past year.
* Revenue: ₹469 Crore (TTM). The company has achieved an outstanding annual revenue growth of 60%.
* Net Profit: ₹90.7 Crore.
* Return on Equity (ROE): The company boasts an exceptional ROE of 35%, with a 3-year ROE of 40.6%.
* PE Ratio: The latest PE ratio stands at 58.41 (as of July 01, 2025).
* Promoter Holding: 63.5%. Promoter holding has seen a decrease of -2.31% over the last quarter.
The company's operating revenue stands at Rs. 900.65 Cr on a trailing 12-month basis, supported by a pre-tax margin of 29%.
Jeena Sikho Lifecare has consistently delivered strong profit growth, achieving a Compound Annual Growth Rate (CAGR) of 73.8% over the last five years. This sustained performance across various business cycles highlights the company's resilience and effective management.
Financially, the company is almost debt-free, possessing a strong balance sheet that enables stable earnings growth. The company's stock performance has been impressive, with a 7.77% increase in share price over the past six months and a remarkable 113.09% increase in the last year. The 52-week high for the stock was ₹499.72, and the 52-week low was ₹199.5.
Jeena Sikho Lifecare Ltd has undertaken significant corporate actions and strategic initiatives:
* Stock Split: A 5:1 stock split was announced, with a record date set for June 12, 2025.
* Dividend: A final dividend of ₹5.47 per share has been recommended, subject to shareholder approval.
* Research and Development: The company is actively engaged in R&D, evidenced by:
* Publication of 10 Ayurvedic research articles on azoospermia and chronic kidney disease management (June 30, 2025).
* Approval of a clinical trial for the diabetes tablet 'Shuddhi Dr. Madhumeh' with 40 participants over three months (June 26, 2025).
Jeena Sikho Lifecare's valuation metrics suggest strong market confidence and future growth potential. The stock trading at 24.1 times its book value indicates investor optimism. The company's debt-free status and robust cash flow generation provide a solid foundation for its expansion plans.
While debtor days have seen an increase from 54.0 to 76.0 days, this is viewed within the context of the company's overall strong profitability and growth trajectory.
Jeena Sikho Lifecare continues to solidify its position in India's expanding healthcare sector, particularly within the Ayurvedic segment. Its comprehensive network of hospitals and clinics, coupled with a diverse product portfolio, effectively addresses various health needs across the country, making it a noteworthy player in the Indian healthcare landscape.
